Industry / Pharmaceuticals: Major
Latest filings
8-K
PCYN
Procyon
2 Aug 23
Entry into a Material Definitive Agreement
2:57pm
10-Q
2023 Q3
PCYN
Procyon
15 May 23
Quarterly report
5:01pm
EFFECT
RHHBF
Roche Holding
3 Apr 23
Notice of effectiveness
12:15am
F-6
RHHBF
Roche Holding
21 Mar 23
Registration for ADRs (foreign)
2:07pm
SC TO-T/A
IPSEF
Ipsen
2 Mar 23
Third party tender offer statement (amended)
11:23am
SC TO-T/A
IPSEF
Ipsen
22 Feb 23
Third party tender offer statement (amended)
6:19am
10-Q
2022 Q2
PCYN
Procyon
14 Feb 23
Quarterly report
4:14pm
SC 13G
Oncternal Therapeutics
9 Feb 23
Oncternal Oncology / VANGUARD ownership change
12:00am
SC TO-T
IPSEF
Ipsen
23 Jan 23
Third party tender offer statement
8:11am
8-K
PCYN
Procyon
13 Jan 23
Submission of Matters to a Vote of Security Holders
2:54pm
Upcoming Earnings Releases
News
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
A
ABT
BDX
21 Sep 23
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
ALNY
IONS
RHHBF
7 Sep 23
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
RHHBF
1 Sep 23
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
RHHBF
30 Aug 23
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
BGNE
GILD
ITOS
23 Aug 23
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
RHHBF
23 Aug 23
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
EXEL
IPSEF
RHHBF
21 Aug 23
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
BMY
HALO
JNJ
28 Jul 23
Roche's 1H Earnings Decline On Lower COVID-19 Sales, CFO Says Late-Stage Pipeline Has Gaps That Needs To Be Filled
REGN
RHHBF
27 Jul 23
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
NVO
REGN
RHHBF
26 Jul 23
Transcripts
MKGAF
Earnings call transcript
2022 Q2
8 Aug 22
MKGAF
Earnings call transcript
2022 Q1
13 May 22
MKGAF
Earnings call transcript
2021 Q2
7 Aug 21
Earnings call transcript
2020 Q4
23 Mar 21
MKGAF
Earnings call transcript
2020 Q3
13 Nov 20
Earnings call transcript
2020 Q3
9 Nov 20
Earnings call transcript
2020 Q2
10 Aug 20
AMAG
Earnings call transcript
2020 Q2
9 Aug 20
Earnings call transcript
2020 Q1
11 May 20
AMAG
Earnings call transcript
2020 Q1
11 May 20
Patents
Utility
Modulators of complement activity
RARX
12 Sep 23
Utility
Anti-SIRP-alpha antibodies and related methods
FTSV
12 Sep 23
Utility
Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile
PRNB
7 Sep 23
Utility
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
FTSV
31 Aug 23
Utility
Modulators of complement activity
RARX
15 Aug 23
Utility
Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy
FTSV
8 Aug 23
Utility
Modulators of complement activity
RARX
25 Jul 23
Utility
Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
PRNB
25 Jul 23
Utility
Treatment of Acute Respiratory Distress Syndrome and Other Disorders Involving Cytokine Storm Using BTK Inhibitors
PRNB
25 May 23
Utility
Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
PRNB
25 May 23